Thursday , 18 October 2018
Breaking News
Home » Tag Archives: biotech.com

Tag Archives: biotech.com

Data Presented at the Annual Meeting of the Asian Academy of Neurology Specialists Offers Additional Support for Plasma Exchange.

logo Braincure-Biotech.com

Taipei; 31, December 2015: Braincure-Biotech.com (ISIN:TW0001327872) reports additional findings from a study which shows that plasma exchange accelerates the removal of relapsing forms of MS (multiple sclerosis) from blood serum in patients and may help improve central nervous system immune response based on an in vitro model. The data was presented today at the Annual Meeting of the Asian Academy ... Read More »

Researchers Report Artemin Virtually Restores Complete Long-Term Sensory Motor Function in Preclinical Studies

logo Braincure-Biotech.com

Taipei; 30, December 2015: Braincure-Biotech.com (ISIN:TW0001327872) reported that in preclinical studies, injections of the protein Artemin promoted the regeneration of damaged sensory nerve cells and produced virtually complete, long-term restoration of sensory and motor function. Artemin, also known as Neublastin, belongs to a family of proteins, called glial-derived neurotrophic factors, which promote nerve cell survival. The protein is unique because ... Read More »

Chen D. Gou to Become Chairman of Braincure-Biotech.com

logo Braincure-Biotech.com

Taipei; 26, December 2015: Braincure Biotech (ISIN:TW0001327872) has recently appointed Chen D. Gou will become Chairman of the Company’s Board of Directors, effective immediately. The appointment follows the decision by Tsao T. Wenjung, 65, the Company’s former Chairman, to retire from his position. Mr. Wenjung will retire from the Board at the Company’s Annual Shareholder Meeting. The Board stated, “We ... Read More »

Genocore-Biotech.com Announce License Agreement to Develop Novel Inhibitor of Vascular Protein

logo Genocore-Biotech-com

Shenzhen; 28, December 2015: Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs, today announced an agreement for the further development of a novel, oral small molecule inhibitor of Vascular Protein 1, a cell molecule that may be effective in the treatment of inflammatory diseases. The inhibitor is ... Read More »

Braincure-Biotech.com Names Lee Yung Lung Chief Operating Officer

logo Braincure-Biotech.com

Taipei; 28, December 2015: Braincure Biotech (ISIN:TW0001327872) has recently appointed Mr. Lee Yung Lung as the Chief Operating Officer (COO) of the company. Mr. Lung, age 53, has served as Executive Vice President, Global Neurology and Head of International. In his new role, Mr. Lung will oversee all commercial operations as well as the company’s business development function. “In view ... Read More »

Genocore-Biotech.com Foundation Announces $250.000 Gift to Biotechnology Center

logo Genocore-Biotech-com

Shenzhen; 26, December 2015: Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs), today announced it has awarded a $250.000 Transformational Grant in Science Education to the Biotechnology Center to support the expansion of the Center’s educational training facility for science teachers. The grant is part of the Genocore Biotech Foundation’s new ... Read More »

Genocore-Biotech.com Appoints Hon Wen Long, M.D., to Scientific Advisory Board

logo Genocore-Biotech-com

Shenzhen; 26, December 2015: Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody, today announced that the company has appointed HonWen Long, M.D., to its Scientific Advisory Board. Dr. Wen Long is a preeminent researcher with expertise in device-based research for Neuropsychiatric Disorders.Currently Dr. Wen Long is Professor of Psychiatry, Neurology & Medicine. ... Read More »

Genocore-Biotech.com Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial

logo Genocore-Biotech-com

23, December 2015: Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs), today announced that they plan to advance the companies’ Hemophilia B therapy a registrational clinical trial in hemophilia B patients. The decision to advance the program is based on promising data from a pharmacokinetic study in severe, previously-treated hemophilia B ... Read More »

Genocore-Biotech.com and Top Pharmaceutical Research Company Announce Collaboration Agreement to Develop and Commercialize Multiple Sclerosis Therapy (MST)

Shenzhen; 22, December 2015: Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs, today announced that they have entered into an exclusive collaboration and license agreement to develop and commercialize a multiple sclerosis (MS) therapy. The therapy is a novel, oral sustained-release compound being developed to improve walking ... Read More »